Keywords: Elan, Boehringer Ingelheim, Antibody-based therapeutics, Development, Manufacturing
Elan and Boehringer Ingelheim tie-up for antibody-based therapeutic
Article | 10 February 2011
Ireland-based drugmaker Elan (NYSE: ELN) and German family-owned pharma major Boehringer Ingelheim have entered into a global technical development and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
